{
    "id": "dbpedia_5009_3",
    "rank": 94,
    "data": {
        "url": "https://www.nature.com/articles/s41569-024-01064-4",
        "read_more_link": "",
        "language": "en",
        "title": "Mechanisms and treatment of pulmonary arterial hypertension",
        "top_image": "https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41569-024-01064-4/MediaObjects/41569_2024_1064_Fig1_HTML.png",
        "meta_img": "https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41569-024-01064-4/MediaObjects/41569_2024_1064_Fig1_HTML.png",
        "images": [
            "https://pubads.g.doubleclick.net/gampad/ad?iu=/285/naturereviews.cardiology/article&sz=728x90&c=1770339637&t=pos%3Dtop%26type%3Darticle%26artid%3Ds41569-024-01064-4%26doi%3D10.1038/s41569-024-01064-4%26subjmeta%3D1436,243,565,692,699,700,75%26kwrd%3DDrug+therapy,Hypertension",
            "https://media.springernature.com/full/nature-cms/uploads/product/nrcardio/header-d54e1c3c55a369cba4b06862cad6c96d.svg",
            "https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41569-024-01064-4/MediaObjects/41569_2024_1064_Fig1_HTML.png",
            "https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41569-024-01064-4/MediaObjects/41569_2024_1064_Fig2_HTML.png",
            "https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41569-024-01064-4/MediaObjects/41569_2024_1064_Fig3_HTML.png",
            "https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41572-023-00486-7/MediaObjects/41572_2023_486_Fig1_HTML.png",
            "https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41598-020-65697-4/MediaObjects/41598_2020_65697_Fig1_HTML.png",
            "https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41467-019-13139-9/MediaObjects/41467_2019_13139_Fig1_HTML.png",
            "https://pubads.g.doubleclick.net/gampad/ad?iu=/285/naturereviews.cardiology/article&sz=300x250&c=-1563457969&t=pos%3Dright%26type%3Darticle%26artid%3Ds41569-024-01064-4%26doi%3D10.1038/s41569-024-01064-4%26subjmeta%3D1436,243,565,692,699,700,75%26kwrd%3DDrug+therapy,Hypertension",
            "https://www.nature.com/static/images/logos/sn-logo-white-ea63208b81.svg",
            "https://www.nature.com/static/images/logos/nature-briefing-logo-n150-white-d81c9da3ec.svg",
            "https://verify.nature.com/verify/nature.png",
            "https://www.nature.com/c5iq0v07/preview/s41569-024-01064-4"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Hossein-Ardeschir",
            "Gomberg-Maitland"
        ],
        "publish_date": "2024-08-07T00:00:00",
        "summary": "",
        "meta_description": "Substantial progress has been made in the management of pulmonary arterial hypertension (PAH) in the past 25 years, but the disease remains life-limiting. Established therapies for PAH are mostly limited to symptomatic relief by correcting the imbalance of vasoactive factors. The tyrosine kinase inhibitor imatinib, the first predominantly non-vasodilatory drug to be tested in patients with PAH, improved exercise capacity and pulmonary haemodynamics compared with placebo but at the expense of adverse events such as subdural haematoma. Given that administration by inhalation might reduce the risk of systemic adverse effects, inhaled formulations of tyrosine kinase inhibitors are currently in clinical development. Other novel therapeutic approaches for PAH include suppression of activin receptor type IIA signalling with sotatercept, which has shown substantial efficacy in clinical trials and was approved for use in the USA in 2024, but the long-term safety of the drug remains unclear. Future advances in the management of PAH will focus on right ventricular function and involve deep phenotyping and the development of a personalized medicine approach. In this Review, we summarize the mechanisms underlying PAH, provide an overview of available PAH therapies and their limitations, describe the development of newer, predominantly non-vasodilatory drugs that are currently being tested in phase II or III clinical trials, and discuss future directions for PAH research. In this Review, Ghofrani and colleagues discuss the mechanisms underlying the development of pulmonary arterial hypertension, provide an overview of approved therapies and describe the predominantly non-vasodilatory drugs that are currently being tested in clinical trials.",
        "meta_lang": "en",
        "meta_favicon": "/static/images/favicons/nature/apple-touch-icon-f39cb19454.png",
        "meta_site_name": "Nature",
        "canonical_link": "https://www.nature.com/articles/s41569-024-01064-4",
        "text": "Hemnes, A. R. et al. Clinical characteristics and transplant-free survival across the spectrum of pulmonary vascular disease. J. Am. Coll. Cardiol. 80, 697–718 (2022).\n\nSommer, N. et al. Current and future treatments of pulmonary arterial hypertension. Br. J. Pharmacol. 178, 6–30 (2021).\n\nNaeije, R., Richter, M. J. & Rubin, L. J. The physiological basis of pulmonary arterial hypertension. Eur. Respir. J. 59, 2102334 (2022).\n\nLahm, T. et al. Assessment of right ventricular function in the research setting: knowledge gaps and pathways forward. An official American Thoracic Society research statement. Am. J. Respir. Crit. Care Med. 198, e15–e43 (2018).\n\nHumbert, M. et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 43, 3618–3731 (2022).\n\nOpitz, C. F. et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J. Am. Coll. Cardiol. 68, 368–378 (2016).\n\nHoeper, M. M. et al. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respir. Med. 10, 937–948 (2022).\n\nUS Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. Biologic License Application (BLA): 761363 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761363 (2024).\n\nMorrell, N. W. et al. Genetics and genomics of pulmonary arterial hypertension. Eur. Respir. J. 53, 1801899 (2019).\n\nTheilmann, A. L. et al. Endothelial BMPR2 loss drives a proliferative response to BMP (bone morphogenetic protein) 9 via prolonged canonical signaling. Arterioscler. Thromb. Vasc. Biol. 40, 2605–2618 (2020).\n\nHiepen, C. et al. BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGFβ responses and altered cell mechanics. PLoS Biol. 17, e3000557 (2019).\n\nHopper, R. K. et al. In pulmonary arterial hypertension, reduced BMPR2 promotes endothelial-to-mesenchymal transition via HMGA1 and its target slug. Circulation 133, 1783–1794 (2016).\n\nYang, X. et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ. Res. 96, 1053–1063 (2005).\n\nTrembath, R. C. et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N. Engl. J. Med. 345, 325–334 (2001).\n\nHarrison, R. E. et al. Transforming growth factor-β receptor mutations and pulmonary arterial hypertension in childhood. Circulation 111, 435–441 (2005).\n\nChaouat, A. et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 59, 446–448 (2004).\n\nGraf, S. et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat. Commun. 9, 1416 (2018).\n\nArcher, S. L. et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 121, 2661–2671 (2010).\n\nLiu, D. et al. Hypermethylation of BMPR2 promoter occurs in patients with heritable pulmonary arterial hypertension and inhibits BMPR2 expression. Am. J. Respir. Crit. Care Med. 196, 925–928 (2017).\n\nCook, E. K. et al. DNMT3A and TET2 mutations: linking genetics and epigenetics in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 199, A2397 (2019).\n\nPotus, F. et al. Novel mutations and decreased expression of the epigenetic regulator TET2 in pulmonary arterial hypertension. Circulation 141, 1986–2000 (2020).\n\nEmon, I. M., Al-Qazazi, R., Rauh, M. J. & Archer, S. L. The role of clonal hematopoiesis of indeterminant potential and DNA (Cytosine-5)-methyltransferase dysregulation in pulmonary arterial hypertension and other cardiovascular diseases. Cells 12, 2528 (2023).\n\nChelladurai, P. et al. Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy. Br. J. Pharmacol. 178, 54–71 (2021).\n\nZhao, L. et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 126, 455–467 (2012).\n\nBoucherat, O. et al. HDAC6: a novel histone deacetylase implicated in pulmonary arterial hypertension. Sci. Rep. 7, 4546 (2017).\n\nPaulin, R. et al. Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans. Cell Metab. 20, 827–839 (2014).\n\nMeloche, J. et al. Bromodomain-containing protein 4: the epigenetic origin of pulmonary arterial hypertension. Circ. Res. 117, 525–535 (2015).\n\nBernardi, N., Bianconi, E., Vecchi, A. & Ameri, P. Noncoding RNAs in pulmonary arterial hypertension: current knowledge and translational perspectives. Heart Fail. Clin. 19, 137–152 (2023).\n\nLe Ribeuz, H. et al. In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression. Respir. Res. 21, 186 (2020).\n\nSubstance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health. https://www.samhsa.gov/data/ (Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, 2020).\n\nEuropean Monitoring for Drugs and Drug Addiction & Europol. EU drug market: methamphetamine — in-depth analysis. https://www.emcdda.europa.eu/publications/eu-drug-markets/methamphetamine_en (2022).\n\nChin, K. M., Channick, R. N. & Rubin, L. J. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 130, 1657–1663 (2006).\n\nRothman, R. B., Ayestas, M. A., Dersch, C. M. & Baumann, M. H. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 100, 869–875 (1999).\n\nRothman, R. B. et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39, 32–41 (2001).\n\nEddahibi, S. et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113, 1857–1864 (2006).\n\nBousvaros, G. A. Effects of norepinephrine on human pulmonary circulation. Br. Heart J. 24, 738–744 (1962).\n\nRose, J. C. & Lazaro, E. J. Pulmonary vascular responses to serotonin and effects of certain serotonin antagonists. Circ. Res. 6, 283–288 (1958).\n\nLiu, R. et al. Norepinephrine stimulation of alpha1D-adrenoceptor promotes proliferation of pulmonary artery smooth muscle cells via ERK-1/2 signaling. Int. J. Biochem. Cell Biol. 88, 100–112 (2017).\n\nMontani, D. et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125, 2128–2137 (2012).\n\nCribbs, S. K., Crothers, K. & Morris, A. Pathogenesis of HIV-related lung disease: immunity, infection, and inflammation. Physiol. Rev. 100, 603–632 (2020).\n\nFerrari, T. C. A., Albricker, A. C. L., Goncalves, I. M. & Freire, C. M. V. Schistosome-associated pulmonary arterial hypertension: a review emphasizing pathogenesis. Front. Cardiovasc. Med. 8, 724254 (2021).\n\nChalifoux, L. V. et al. Arteriopathy in macaques infected with simian immunodeficiency virus. Lab. Invest. 67, 338–349 (1992).\n\nMarecki, J. C. et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am. J. Respir. Crit. Care Med. 174, 437–445 (2006).\n\nKanmogne, G. D., Primeaux, C. & Grammas, P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem. Biophys. Res. Commun. 333, 1107–1115 (2005).\n\nMermis, J. et al. Hypoxia-inducible factor-1 α/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling. Respir. Res. 12, 103 (2011).\n\nKuebler, W. M., Bonnet, S. & Tabuchi, A. Inflammation and autoimmunity in pulmonary hypertension: is there a role for endothelial adhesion molecules? (2017 Grover Conference Series). Pulm. Circ. 8, 2045893218757596 (2018).\n\nLin, C. Y., Ko, C. H., Hsu, C. Y. & Chen, H. A. Epidemiology and mortality of connective tissue disease-associated pulmonary arterial hypertension: a national cohort study in Taiwan. Semin. Arthritis Rheum. 50, 957–962 (2020).\n\nLi, M., Tan, Y., Stenmark, K. R. & Tan, W. High pulsatility flow induces acute endothelial inflammation through overpolarizing cells to activate NF-κB. Cardiovasc. Eng. Technol. 4, 26–38 (2013).\n\nSavai, R. et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 186, 897–908 (2012).\n\nHuang, W. et al. Mechanical stretching of the pulmonary vein mediates pulmonary hypertension due to left heart disease by regulating SAC/MAPK pathway and the expression of IL-6 and TNF-α. J. Cardiothorac. Surg. 16, 127 (2021).\n\nLiu, S. F. et al. Pulmonary hypertension: linking inflammation and pulmonary arterial stiffening. Front. Immunol. 13, 959209 (2022).\n\nHester, J., Ventetuolo, C. & Lahm, T. Sex, gender, and sex hormones in pulmonary hypertension and right ventricular failure. Compr. Physiol. 10, 125–170 (2019).\n\nAustin, E. D. et al. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur. Respir. J. 34, 1093–1099 (2009).\n\nBaird, G. L. et al. Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension. Eur. Respir. J. 51, 1800467 (2018).\n\nVentetuolo, C. E. et al. Higher estradiol and lower dehydroepiandrosterone-sulfate levels are associated with pulmonary arterial hypertension in men. Am. J. Respir. Crit. Care Med. 193, 1168–1175 (2016).\n\nWu, W. H. et al. Impact of pituitary-gonadal axis hormones on pulmonary arterial hypertension in men. Hypertension 72, 151–158 (2018).\n\nFrump, A. L. et al. 17β-Estradiol and estrogen receptor α protect right ventricular function in pulmonary hypertension via BMPR2 and apelin. J. Clin. Invest. 131, e129433 (2021).\n\nVentetuolo, C. E. et al. Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function. Eur. Respir. J. 47, 553–563 (2016).\n\nVentetuolo, C. E. et al. Sex hormones are associated with right ventricular structure and function: the MESA-right ventricle study. Am. J. Respir. Crit. Care Med. 183, 659–667 (2011).\n\nRhodes, C. J. et al. Plasma metabolomics implicates modified transfer RNAs and altered bioenergetics in the outcomes of pulmonary arterial hypertension. Circulation 135, 460–475 (2017).\n\nMiller, J. L. Iron deficiency anemia: a common and curable disease. Cold Spring Harb. Perspect. Med. 3, a011866 (2013).\n\nRhodes, C. J. et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J. Am. Coll. Cardiol. 58, 300–309 (2011).\n\nRuiter, G. et al. Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology 53, 285–292 (2014).\n\nKrasuski, R. A. et al. Association of anemia and long-term survival in patients with pulmonary hypertension. Int. J. Cardiol. 150, 291–295 (2011).\n\nLiu, J. et al. Prognostic impact of red blood cell distribution width in pulmonary hypertension patients: a systematic review and meta-analysis. Medicine 99, e19089 (2020).\n\nAllen, B. J. et al. Biomechanical and mechanobiological drivers of the transition from postcapillary pulmonary hypertension to combined pre-/postcapillary pulmonary hypertension. J. Am. Heart Assoc. 12, e028121 (2023).\n\nSchafer, M. et al. Main pulmonary arterial wall shear stress correlates with invasive hemodynamics and stiffness in pulmonary hypertension. Pulm. Circ. 6, 37–45 (2016).\n\nLi, M., Stenmark, K. R., Shandas, R. & Tan, W. Effects of pathological flow on pulmonary artery endothelial production of vasoactive mediators and growth factors. J. Vasc. Res. 46, 561–571 (2009).\n\nCheng, C. et al. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 113, 2744–2753 (2006).\n\nBassiouny, H. S. et al. Flow regulation of 72-kD collagenase IV (MMP-2) after experimental arterial injury. Circulation 98, 157–163 (1998).\n\nQi, Y. X. et al. PDGF-BB and TGF-β1 on cross-talk between endothelial and smooth muscle cells in vascular remodeling induced by low shear stress. Proc. Natl Acad. Sci. USA 108, 1908–1913 (2011).\n\nLiu, W. F., Nelson, C. M., Tan, J. L. & Chen, C. S. Cadherins, RhoA, and Rac1 are differentially required for stretch-mediated proliferation in endothelial versus smooth muscle cells. Circ. Res. 101, e44–e52 (2007).\n\nvon Offenberg Sweeney, N. et al. Cyclic strain-mediated regulation of endothelial matrix metalloproteinase-2 expression and activity. Cardiovasc. Res. 63, 625–634 (2004).\n\nHatami, J., Tafazzoli-Shadpour, M., Haghighipour, N., Shokrgozar, M. A. & Janmaleki, M. Influence of cyclic stretch on mechanical properties of endothelial cells. Experimental Mechanics 53, 1291–1298 (2013).\n\nOmidvar, R., Tafazzoli-Shadpour, M., Mahmoodi-Nobar, F., Azadi, S. & Khani, M. M. Quantifying effects of cyclic stretch on cell-collagen substrate adhesiveness of vascular endothelial cells. Proc. Inst. Mech. Eng. H. 232, 531–541 (2018).\n\nHuertas, A. et al. Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: highlights from basic research to therapy. Eur. Respir. J. 51, 1700745 (2018).\n\nMarsden, P. A., Danthuluri, N. R., Brenner, B. M., Ballermann, B. J. & Brock, T. A. Endothelin action on vascular smooth muscle involves inositol trisphosphate and calcium mobilization. Biochem. Biophys. Res. Commun. 158, 86–93 (1989).\n\nPark, W. S., Ko, E. A., Han, J., Kim, N. & Earm, Y. E. Endothelin-1 acts via protein kinase C to block KATP channels in rabbit coronary and pulmonary arterial smooth muscle cells. J. Cardiovasc. Pharmacol. 45, 99–108 (2005).\n\nTai, K. et al. Agonist-evoked calcium entry in vascular smooth muscle cells requires IP3 receptor-mediated activation of TRPC1. Eur. J. Pharmacol. 583, 135–147 (2008).\n\nArcher, S. L. et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA 91, 7583–7587 (1994).\n\nHampl, V., Huang, J. M., Weir, E. K. & Archer, S. L. Activation of the cGMP-dependent protein kinase mimics the stimulatory effect of nitric oxide and cGMP on calcium-gated potassium channels. Physiol. Res. 44, 39–44 (1995).\n\nCohen, R. A. et al. Mechanism of nitric oxide-induced vasodilatation: refilling of intracellular stores by sarcoplasmic reticulum Ca2+ ATPase and inhibition of store-operated Ca2+ influx. Circ. Res. 84, 210–219 (1999).\n\nChen, J., Crossland, R. F., Noorani, M. M. & Marrelli, S. P. Inhibition of TRPC1/TRPC3 by PKG contributes to NO-mediated vasorelaxation. Am. J. Physiol. Heart Circ. Physiol. 297, H417–H424 (2009).\n\nOlschewski, A. et al. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ. Res. 98, 1072–1080 (2006).\n\nLe Hiress, M. et al. Proinflammatory signature of the dysfunctional endothelium in pulmonary hypertension. role of the macrophage migration inhibitory factor/CD74 complex. Am. J. Respir. Crit. Care Med. 192, 983–997 (2015).\n\nBowers, R. et al. Oxidative stress in severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 169, 764–769 (2004).\n\nAltman, R. et al. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clin. Cardiol. 19, 549–554 (1996).\n\nBoucherat, O. et al. The cancer theory of pulmonary arterial hypertension. Pulm. Circ. 7, 285–299 (2017).\n\nHumbert, M. et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur. Respir. J. 53, 1801887 (2019).\n\nVoelkel, N. F. & Gomez-Arroyo, J. The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox. Am. J. Respir. Cell Mol. Biol. 51, 474–484 (2014).\n\nPerros, F. et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178, 81–88 (2008).\n\nHumbert, M. et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur. Respir. J. 11, 554–559 (1998).\n\nHumbert, M. et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 151, 1628–1631 (1995).\n\nParpaleix, A. et al. Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension. Eur. Respir. J. 48, 470–483 (2016).\n\nAmeshima, S. et al. Peroxisome proliferator-activated receptor gamma (PPARγ) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ. Res. 92, 1162–1169 (2003).\n\nvan der Bruggen, C. E. et al. Bone morphogenetic protein receptor type 2 mutation in pulmonary arterial hypertension: a view on the right ventricle. Circulation 133, 1747–1760 (2016).\n\nVonk Noordegraaf, A. et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur. Respir. J. 53, 1801900 (2019).\n\nPotus, F. et al. Downregulation of microRNA-126 contributes to the failing right ventricle in pulmonary arterial hypertension. Circulation 132, 932–943 (2015).\n\nSutendra, G. et al. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J. Mol. Med. 91, 1315–1327 (2013).\n\nUmar, S. et al. Estrogen rescues preexisting severe pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 184, 715–723 (2011).\n\nFrump, A. L. et al. Estradiol improves right ventricular function in rats with severe angioproliferative pulmonary hypertension: effects of endogenous and exogenous sex hormones. Am. J. Physiol. Lung Cell. Mol. Physiol. 308, L873–L890 (2015).\n\nLahm, T. et al. 17β-Estradiol mediates superior adaptation of right ventricular function to acute strenuous exercise in female rats with severe pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 311, L375–L388 (2016).\n\nLiu, A. et al. Direct and indirect protection of right ventricular function by estrogen in an experimental model of pulmonary arterial hypertension. Am. J. Physiol. Heart Circ. Physiol. 307, H273–H283 (2014).\n\nAgrawal, V., Lahm, T., Hansmann, G. & Hemnes, A. R. Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose/lipid metabolism. Cardiovasc. Diagn. Ther. 10, 1522–1540 (2020).\n\nPrins, K. W. et al. Colchicine depolymerizes microtubules, increases junctophilin-2, and improves right ventricular function in experimental pulmonary arterial hypertension. J. Am. Heart Assoc. 6, e006195 (2017).\n\nRain, S. et al. Right ventricular diastolic impairment in patients with pulmonary arterial hypertension. Circulation 128, 2016–2025 (2013).\n\nHsu, S. et al. Right ventricular myofilament functional differences in humans with systemic sclerosis-associated versus idiopathic pulmonary arterial hypertension. Circulation 137, 2360–2370 (2018).\n\nPrisco, S. Z., Thenappan, T. & Prins, K. W. Treatment targets for right ventricular dysfunction in pulmonary arterial hypertension. JACC Basic Transl. Sci. 5, 1244–1260 (2020).\n\nSydykov, A. et al. Inflammatory mediators drive adverse right ventricular remodeling and dysfunction and serve as potential biomarkers. Front. Physiol. 9, 609 (2018).\n\nPrins, K. W. et al. Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. J. Heart Lung Transplant. 37, 376–384 (2018).\n\nYang, T. et al. Increased levels of plasma CXC-chemokine ligand 10, 12 and 16 are associated with right ventricular function in patients with idiopathic pulmonary arterial hypertension. Heart Lung 43, 322–327 (2014).\n\nAl-Qazazi, R. et al. Macrophage-NLRP3 activation promotes right ventricle failure in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 206, 608–624 (2022).\n\nBekedam, F. T., Goumans, M. J., Bogaard, H. J., de Man, F. S. & Llucia-Valldeperas, A. Molecular mechanisms and targets of right ventricular fibrosis in pulmonary hypertension. Pharmacol. Ther. 244, 108389 (2023).\n\nOikawa, M. et al. Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J. Am. Coll. Cardiol. 45, 1849–1855 (2005).\n\nPiao, L. et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J. Mol. Med. 88, 47–60 (2010).\n\nBrittain, E. L. et al. Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension. Circulation 133, 1936–1944 (2016).\n\nTalati, M. H. et al. Mechanisms of lipid accumulation in the bone morphogenetic protein receptor type 2 mutant right ventricle. Am. J. Respir. Crit. Care Med. 194, 719–728 (2016).\n\nGraham, B. B. et al. Severe pulmonary hypertension is associated with altered right ventricle metabolic substrate uptake. Am. J. Physiol. Lung Cell. Mol. Physiol. 309, L435–L440 (2015).\n\nHemnes, A. R. et al. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 189, 325–334 (2014).\n\nBarst, R. J. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N. Engl. J. Med. 334, 296–301 (1996).\n\nSimonneau, G. et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 165, 800–804 (2002).\n\nOlschewski, H. et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347, 322–329 (2002).\n\nMcLaughlin, V. V. et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J. Am. Coll. Cardiol. 55, 1915–1922 (2010).\n\nJing, Z. C. et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 127, 624–633 (2013).\n\nLaliberte, K., Arneson, C., Jeffs, R., Hunt, T. & Wade, M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J. Cardiovasc. Pharmacol. 44, 209–214 (2004).\n\nBenza, R. L. et al. One-year experience with intravenous treprostinil for pulmonary arterial hypertension. J. Heart Lung Transplant. 32, 889–896 (2013).\n\nSitbon, O. et al. Selexipag for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 373, 2522–2533 (2015).\n\nRubin, L. J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896–903 (2002).\n\nGalie, N. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117, 3010–3019 (2008).\n\nPulido, T. et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N. Engl. J. Med. 369, 809–818 (2013).\n\nGalie, N. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353, 2148–2157 (2005).\n\nGalie, N. et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119, 2894–2903 (2009).\n\nGhofrani, H. A. et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 369, 330–340 (2013).\n\nGalie, N. et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N. Engl. J. Med. 373, 834–844 (2015).\n\nSitbon, O. et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur. Respir. J. 47, 1727–1736 (2016).\n\nHoeper, M. M. et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir. Med. 9, 573–584 (2021).\n\nHoeper, M. M. et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur. Respir. J. 50, 1602425 (2017).\n\nChin, K. M. et al. Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. J. Am. Coll. Cardiol. 78, 1393–1403 (2021).\n\nWei, A. et al. Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials. J. Am. Heart Assoc. 5, e003896 (2016).\n\nSitbon, O. et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111, 3105–3111 (2005).\n\nGerhardt, F. et al. Positive vasoreactivity testing in pulmonary arterial hypertension: therapeutic consequences, treatment patterns, and outcomes in the modern management era. Circulation 149, 1549–1564 (2024).\n\nCapdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493–502 (2002).\n\nCohen, M. H. et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8, 935–942 (2002).\n\nYu, Y. et al. PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. Am. J. Physiol. Cell Physiol. 284, C316–C330 (2003).\n\nSchermuly, R. T. et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 115, 2811–2821 (2005).\n\nGhofrani, H. A., Seeger, W. & Grimminger, F. Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 353, 1412–1413 (2005).\n\nPatterson, K. C., Weissmann, A., Ahmadi, T. & Farber, H. W. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann. Intern. Med. 145, 152–153 (2006).\n\nSouza, R., Sitbon, O., Parent, F., Simonneau, G. & Humbert, M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 61, 736 (2006).\n\nGhofrani, H. A. et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am. J. Respir. Crit. Care Med. 182, 1171–1177 (2010).\n\nHoeper, M. M. et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 127, 1128–1138 (2013).\n\nGillies, H. et al. AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study. ERJ Open Res. 9, 00433-2022 (2023).\n\nUS National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05036135 (2024).\n\nWilkins, M. R. et al. Positioning imatinib for pulmonary arterial hypertension: a phase I/II design comprising dose finding and single-arm efficacy. Pulm. Circ. 11, 20458940211052823 (2021).\n\nGalkin, A. et al. Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension. Eur. Respir. J. 60, 2102356 (2022).\n\nFrantz, R. P. et al. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir. Med. https://doi.org/10.1016/S2213-2600(24)00072-9 (2024).\n\nUS National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05934526 (2024).\n\nHumbert, M. et al. Sotatercept for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 384, 1204–1215 (2021).\n\nHumbert, M. et al. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur. Respir. J. 61, 2201347 (2023).\n\nYung, L. M. et al. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. Sci. Transl. Med. 12, eaaz5660 (2020).\n\nHoeper, M. M. et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N. Engl. J. Med. 388, 1478–1490 (2023).\n\nDogra, D. et al. Opposite effects of Activin type 2 receptor ligands on cardiomyocyte proliferation during development and repair. Nat. Commun. 8, 1902 (2017).\n\nUS National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04796337 (2023).\n\nUS National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04896008 (2023).\n\nUS National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04811092 (2024).\n\nHodgson, J. et al. Characterization of GDF2 mutations and levels of BMP9 and BMP10 in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 201, 575–585 (2020).\n\nMorrell, N. W. et al. MGX292, a novel variant of native bone morphogenetic protein 9 (BMP9) that lacks osteogenic activity, reverses vascular remodelling and pulmonary arterial hypertension in the sugen-hypoxia rat model. Am. J. Respir. Crit. Care Med. 207, A6729 (2023).\n\nLong, L. et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat. Med. 21, 777–785 (2015).\n\nJiang, Q. et al. Dysregulation of BMP9/BMPR2/SMAD signalling pathway contributes to pulmonary fibrosis and pulmonary hypertension induced by bleomycin in rats. Br. J. Pharmacol. 178, 203–216 (2021).\n\nTu, L. et al. Selective BMP-9 inhibition partially protects against experimental pulmonary hypertension. Circ. Res. 124, 846–855 (2019).\n\nBouvard, C. et al. Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. Cardiovasc. Res. 118, 1805–1820 (2022).\n\nMorrell, N. W., Upton, P. D., Li, W. & Yu, P. B. Letter by morrell et al regarding article, “selective bmp-9 inhibition partially protects against experimental pulmonary hypertension”. Circ. Res. 124, e81 (2019).\n\nWang, L. et al. BMP9 and BMP10 act directly on vascular smooth muscle cells for generation and maintenance of the contractile state. Circulation 143, 1394–1410 (2021).\n\nUpton, P. D., Dunmore, B. J., Li, W. & Morrell, N. W. An emerging class of new therapeutics targeting TGF, Activin, and BMP ligands in pulmonary arterial hypertension. Dev. Dyn. 252, 327–342 (2023).\n\nMair, K. M. et al. Sex-dependent influence of endogenous estrogen in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 190, 456–467 (2014).\n\nKawut, S. M. et al. Anastrozole in pulmonary arterial hypertension. a randomized, double-blind, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 195, 360–368 (2017).\n\nKawut, S. M. et al. Pulmonary hypertension and anastrozole (phantom): a randomized clinical trial. Am. J. Respir. Crit. Care Med. 207, A6727 (2023).\n\nChen, X. et al. Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects. Eur. Respir. J. 50, 1602337 (2017).\n\nUS National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03528902 (2023).\n\nAlzoubi, A. et al. Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension. Am. J. Physiol. Heart Circ. Physiol. 304, H1708–H1718 (2013).\n\nBonnet, S. et al. Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc. Natl Acad. Sci. USA 100, 9488–9493 (2003).\n\nHampl, V., Bibova, J., Povysilova, V. & Herget, J. Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats. Eur. Respir. J. 21, 862–865 (2003).\n\nZhang, Y. T. et al. Dehydroepiandrosterone attenuates pulmonary artery and right ventricular remodeling in a rat model of pulmonary hypertension due to left heart failure. Life Sci. 219, 82–89 (2019).\n\nDumas de La Roque, E. et al. Dehydroepiandrosterone (DHEA) improves pulmonary hypertension in chronic obstructive pulmonary disease (COPD): a pilot study. Ann. Endocrinol. 73, 20–25 (2012).\n\nWalsh, T. P. et al. Experimental design of the effects of dehydroepiandrosterone in pulmonary hypertension (EDIPHY) trial. Pulm. Circ. 11, 2045894021989554 (2021).\n\nUS National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03648385 (2023).\n\nAgard, C. et al. Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. Br. J. Pharmacol. 158, 1285–1294 (2009).\n\nGoncharov, D. A. et al. Metformin therapy for pulmonary hypertension associated with heart failure with preserved ejection fraction versus pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 198, 681–684 (2018).\n\nDean, A., Nilsen, M., Loughlin, L., Salt, I. P. & MacLean, M. R. Metformin reverses development of pulmonary hypertension via aromatase inhibition. Hypertension 68, 446–454 (2016).\n\nLiao, S., Li, D., Hui, Z., McLachlan, C. S. & Zhang, Y. Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study. ERJ Open Res. 4, 00060-2018 (2018).\n\nUS National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03617458 (2023).\n\nMichelakis, E. D. et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 105, 244–250 (2002).\n\nMcMurtry, M. S. et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ. Res. 95, 830–840 (2004).\n\nGuignabert, C. et al. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22α-targeted overexpression of the serotonin transporter. FASEB J. 23, 4135–4147 (2009).\n\nSun, X. Q. et al. Reversal of right ventricular remodeling by dichloroacetate is related to inhibition of mitochondria-dependent apoptosis. Hypertens. Res. 39, 302–311 (2016).\n\nLi, B., Yan, J., Shen, Y., Liu, Y. & Ma, Z. Dichloroacetate prevents but not reverses the formation of neointimal lesions in a rat model of severe pulmonary arterial hypertension. Mol. Med. Rep. 10, 2144–2152 (2014).\n\nMichelakis, E. D. et al. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Sci. Transl. Med. 9, eaao4583 (2017).\n\nJames, M. O. & Stacpoole, P. W. Pharmacogenetic considerations with dichloroacetate dosing. Pharmacogenomics 17, 743–753 (2016).\n\nArcher, S. L., Fang, Y. H., Ryan, J. J. & Piao, L. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm. Circ. 3, 144–152 (2013).\n\nFang, Y. H. et al. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle’s cycle. J. Mol. Med. 90, 31–43 (2012).\n\nVerdejo, H. E. et al. Effects of trimetazidine on right ventricular function and ventricular remodeling in patients with pulmonary artery hypertension: a randomised controlled trial. J. Clin. Med. 12, 1571 (2023).\n\nHerve, P. et al. Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. 99, 249–254 (1995).\n\nAbenhaim, L. et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 335, 609–616 (1996).\n\nLazarus, H. M. et al. A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2). Pulm. Circ. 12, e12088 (2022).\n\nSumitomo Pharma Co. Ltd. Conference on Q1 FY2023 (April 1 to June 30, 2023) Financial Results. https://www.sumitomo-pharma.com/ir/library/presentation/ (2023).\n\nUS National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT04712669 (2023).\n\nAbdul-Salam, V. B. et al. Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation 122, 2058–2067 (2010).\n\nRhodes, C. J. et al. Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respir. Med. 5, 717–726 (2017).\n\nRhodes, C. J. et al. Using the plasma proteome for risk stratifying patients with pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 205, 1102–1111 (2022).\n\nWilkins, M. R. et al. α1-A680T variant in GUCY1A3 as a candidate conferring protection from pulmonary hypertension among Kyrgyz highlanders. Circ. Cardiovasc. Genet. 7, 920–929 (2014).\n\nBohnen, M. S. et al. Loss-of-function ABCC8 mutations in pulmonary arterial hypertension. Circ. Genom. Precis. Med. 11, e002087 (2018).\n\nZhu, N. et al. Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Med. 13, 80 (2021).\n\nRhodes, C. J. et al. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respir. Med. 7, 227–238 (2019).\n\nSmits, A. J. et al. A systematic review with meta-analysis of biomarkers for detection of pulmonary arterial hypertension. ERJ Open Res 8, 00009-2022(2022).\n\nRhodes, C. J. et al. Whole-blood RNA profiles associated with pulmonary arterial hypertension and clinical outcome. Am. J. Respir. Crit. Care Med. 202, 586–594 (2020).\n\nKariotis, S. et al. Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nat. Commun. 12, 7104 (2021).\n\nHemnes, A. R. et al. PVDOMICS: a multi-center study to improve understanding of pulmonary vascular disease through phenomics. Circ. Res. 121, 1136–1139 (2017).\n\nMajeed, R. W. et al. Pulmonary vascular research institute godeep: a meta-registry merging deep phenotyping datafrom international PH reference centers. Pulm. Circ. 12, e12123 (2022).\n\nSavale, L., Guignabert, C., Weatherald, J. & Humbert, M. Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. Eur. Respir. Rev. 27, 180004 (2018).\n\nSwaminathan, A. C. et al. Treatment-related biomarkers in pulmonary hypertension patients on oral therapies. Respir. Res. 21, 304 (2020).\n\nCooke, J. P. ADMA: its role in vascular disease. Vasc. Med. 10 (Suppl. 1), S11–S17 (2005).\n\nGuignabert, C. et al. Serum and pulmonary expression profiles of the activin signaling system in pulmonary arterial hypertension. Circulation 147, 1809–1822 (2023).\n\nBenza, R. L. et al. Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 192, 1345–1354 (2015).\n\nHemnes, A. R. et al. Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation 131, 401–409 (2015).\n\nHoeper, M. M. et al. Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. Eur. Respir. J. 53, 1801906 (2019).\n\nRako, Z. A., Kremer, N., Yogeswaran, A., Richter, M. J. & Tello, K. Adaptive versus maladaptive right ventricular remodelling. ESC Heart Fail. 10, 762–775 (2023).\n\nNagendran, J. et al. Endothelin axis is upregulated in human and rat right ventricular hypertrophy. Circ. Res. 112, 347–354 (2013).\n\nUS National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03362047 (2023).\n\nTello, K. et al. Inhaled iloprost improves right ventricular load-independent contractility in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 206, 111–114 (2022).\n\nNagendran, J. et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116, 238–248 (2007).\n\nHatzimichael, E., Timotheatou, D., Koumpis, E., Benetatos, L. & Makis, A. Luspatercept: a new tool for the treatment of anemia related to β-thalassemia, myelodysplastic syndromes and primary myelofibrosis. Diseases 10, 85 (2022).\n\nBabbs, K., Materna, C., Fisher, F., Seehra, J. & Lachey, J. RKER-012, a novel activin receptor type IIB (ActRIIB) ligand trap, reduced cardiopulmonary pathology in a rodent model of pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 203, A4526 (2021).\n\nNatarajan, H. et al. Administration of KER-012, a modified activin receptor IIB ligand trap, led to changes in biomarkers of cardiovascular health in a ph1 study conducted in healthy post-menopausal women. Am. J. Respir. Crit. Care Med. 207, A1187 (2023).\n\nUS National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05975905 (2024).\n\nTapson, V. F. et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 142, 1383–1390 (2012).\n\nGalie, N. et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 39, 1496–1502 (2002)."
    }
}